D. I/DISTD				_					_
Doi/PMID		1		P R	O	T) C	0	L
10.1002/ / 1.274		osomal							
				T 1 1 1			m . 1		
	Patient characteristics and Doxii dose according to reaction	status					1estea compouna	NT.	D '1/ . 1 . 1!' 11 1! '
	13 TP3	NI	C 1- 2 2	Animai status	Conscious			Name	Doxil (pegylated liposomal doxorubicin)
	13 TP3	Non-reactors		District of sectorial		TATE also and an income			5% Dextrose (250mL)
	13	(n=16)							Acute
		41-/3	38-//	Organism	C	Animai			
		10.146	b 40.20C		-	Human			TT *.
		40-146	40-306			Tt.l			Unique
	Initial dose rate (mg/min)	0.13-0.49	0.13-1.02		Sex	Either		- -	Intravenous
	I3							Comment	infused over 1h
	T3				Age		Other compound	N	
	T3							Name	
	T3								
	$\frac{13}{2}$				Phenotype			Treatment type	
10.1093/annonc/mdg374	T 3				Feeding/drinking			Period:	
	T3					steroids or antihistamines		Frequency:	
	T3				Surgery				
	T3			Comment					
	T3							Comment	
	T3						Inductive agent		
	T3							Name	
	T3							Vehicle	
	T3							Treatment type	
10.1093/annonc/mdg374	T3							Period:	
10.1093/annonc/mdg374	T 3							Frequency:	
10.1093/annonc/mdg374	T3							Administration	
10.1093/annonc/mdg374	T3								
	T3							Comment	
	T3						Parameters of the biological respo	onse	
	T3								Following the start of infusion
	T3								30 min
10.1093/annonc/mdg374	T3								
	T3								Grade of hypersensitivity symptoms (0-4)
	T3								Visual observation
	T3								
10.1093/annonc/mdg374	 Т?						Comment		
	10.1093/annonc/mdg374	Complement activation following first exposure to pegylated lip dexorabic (Doxil); possible role in hypersensitivity reactions of 10.1093/annonc/mdg374	10.1093/annonc/mdg374	Complement activation following first exposure to page lated liponoming 374 13 Doxil Patient characteristics and Doxid preactions Doxid	Complement survivation of the complement of th	Complement of Noting Force register of Force of Special Properties of Special Properti	Companies of Com	Part Part	Company

nduced protocol				Tested compound		
Animal status		Conscious			Name	Doxil (pegylated liposomal doxorubicin
					Vehicle	5% Dextrose (250mL)
Biological material			Whole organism		Treatment type	Acute
	Organism		Animal		Period:	
		Species	Human		Frequency:	
		Strain			Administration	Unique
		Sex	Either		Admin. Type	Intravenous
		Development			Comment	infused over 1h
		Age		Other compound		
		Weight			Name	
		Genotype			Vehicle —	
		Phenotype			Treatment type	
		Feeding/drinking			Period:	
		G	variety of tumors; not premedicated with		T.	
		State	steroids or antihistamines		Frequency:	
		Surgery			Administration	
	Comment				Admin. Type	
				In the other areas	Comment	
				Inductive agent	Name	
					Vehicle	
					Treatment type Period:	
					Frequency: Administration	
					Admin. Type	
					Comment	
				Parameters of the biological response		
				Start time	•	Following the start of infusion
				Duration		30 min
				Measure Type		50 mm
				Measure Object		Grade of hypersensitivity symptoms (0-
				Analysis		Visual observation
				Statistical test		. Idaa oodi varon
				Comment		